Sana Biotechnology Establishes New $150M At-The-Market Equity Offering Program
Summary
Sana Biotechnology filed an S-3ASR to establish a new $150 million at-the-market equity offering program, providing capital for general corporate purposes and R&D.
Key Events
-
New At-The-Market (ATM) Program
Sana Biotechnology established an amended at-the-market (ATM) equity offering program to sell up to $150,000,000 of its common stock from time to time through TD Cowen.
-
Potential Share Dilution
If the entire $150 million is sold at the assumed price of $4.15 per share, approximately 36,144,578 new shares could be issued, representing a potential dilution of about 13.55% to existing shareholders based on 266,731,648 shares outstanding as of December 31, 2025.
-
Use of Proceeds
Net proceeds from the offering are intended for general corporate purposes, including working capital, funding research and development, manufacturing, and capital expenditures, such as preclinical and clinical program initiation and progression.
-
Update to Existing Shelf
This S-3ASR carries forward $216,385,563 of unsold securities from a prior S-3 registration statement filed on March 1, 2024, and amends an existing sales agreement, indicating a continuation and expansion of the company's financing capabilities.
Analysis
Sana Biotechnology has filed an S-3ASR to register a universal shelf offering, including an amended at-the-market (ATM) equity program allowing the company to sell up to $150 million of common stock. This represents a significant potential capital raise, which, if fully utilized, could result in approximately 13.55% dilution for existing shareholders based on current outstanding shares. The proceeds are intended for general corporate purposes, including funding research and development and manufacturing, which is a common need for a life sciences company. This filing updates a previous shelf registration and ATM program, indicating a continuation of the company's financing strategy to secure capital runway.
At the time of this filing, SANA was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.26 to $6.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.